Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Achieve Life Sciences Inc

Healthcare US ACHV

5.01USD
-0.09(1.76%)

Last update at 2026-06-23T20:00:00Z

Day Range

4.865.16
LowHigh

52 Week Range

2.006.03
LowHigh

Fundamentals

  • Previous Close 5.10
  • Market Cap226.27M
  • Volume2123379
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-54.65200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.25

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -54.64800M -39.82700M -29.81500M -42.35000M -33.15200M
Minority interest - - - - -
Net income -54.64800M -39.82700M -29.81500M -41.87500M -32.90200M
Selling general administrative 31.87M 16.25M 11.44M 10.72M 9.13M
Selling and marketing expenses - - 11.20M - -
Gross profit -0.22800M -0.22900M -0.22800M - -
Reconciled depreciation 0.23M 0.23M 0.24M 0.24M 0.25M
Ebit -54.88000M -37.64700M -26.96200M -41.03600M -33.34400M
Ebitda -54.65200M -37.41800M -26.73400M -40.80000M -33.09400M
Depreciation and amortization 0.23M 0.23M 0.23M 0.24M 0.25M
Non operating income net other - - - 0.24M -
Operating income -54.88000M -39.06900M -27.25000M -40.80000M -33.09400M
Other operating expenses 54.88M 39.07M 27.25M 40.80M 33.09M
Interest expense 0.82M 2.18M 2.85M 1.79M 0.02M
Tax provision - - - - -
Interest income 1.50M 2.36M 0.73M 0.20M 0.02M
Net interest income 0.68M 0.18M -1.87800M -1.59000M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -39.82700M - -0.47500M -0.25000M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 54.65M 38.84M 27.25M 40.80M 33.09M
Cost of revenue 0.23M 0.23M 0.23M - -
Total other income expense net 0.23M -0.75800M -2.56500M -1.55000M -0.05800M
Discontinued operations - - - - -
Net income from continuing ops -54.64800M -39.82700M -35.57100M -42.35000M -33.15200M
Net income applicable to common shares - - - -42.35000M -33.15200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 41.79M 38.63M 19.37M 29.97M 47.52M
Intangible assets 0.75M 0.97M 1.20M 1.42M 1.64M
Earning assets - - - - -
Other current assets 3.48M 2.13M 1.32M 2.45M 1.42M
Total liab 20.27M 17.73M 20.82M 21.67M 19.47M
Total stockholder equity 21.52M 20.90M -1.44800M 8.30M 28.04M
Deferred long term liab - - - - -
Other current liab 4.45M 4.68M 3.47M 3.81M 3.64M
Common stock 0.12M 0.10M 0.09M 0.09M 0.08M
Capital stock 0.12M 0.10M 0.09M 0.09M 0.08M
Retained earnings -260.22600M -205.57800M -165.75100M -135.93600M -93.58600M
Other liab - - - - 0.00400M
Good will 1.03M 1.03M 1.03M 1.03M 1.03M
Other assets - - 0.00000M 0.06M 0.18M
Cash 20.93M 12.73M 15.55M 24.77M 43.02M
Cash and equivalents - - - - -
Total current liabilities 9.08M 6.68M 20.81M 5.53M 4.55M
Current deferred revenue - - - - -
Net debt -5.97400M -2.77500M 1.19M -8.57300M -42.94900M
Short term debt 3.77M 0.06M 16.73M 0.06M 0.07M
Short long term debt 3.70M - 16.66M 16.07M -
Short long term debt total 14.96M 9.96M 16.73M 16.20M 0.07M
Other stockholder equity 281.61M 226.34M 164.21M 144.15M 121.55M
Property plant equipment - - - 0.13M 0.06M
Total current assets 39.89M 36.47M 16.98M 24.84M 44.59M
Long term investments - - - - -
Net tangible assets - - - 5.85M 25.37M
Short term investments 15.47M 21.61M - - -
Net receivables - - 0.11M 0.10M 0.15M
Long term debt 11.19M 9.84M - 16.07M 14.92M
Inventory - - - -2.49300M -
Accounts payable 0.87M 1.95M 0.62M 1.66M 0.84M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.01000M 0.03M 0.00400M 0.00400M 0.00400M
Additional paid in capital - - - - -
Common stock total equity - - - 0.09M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -135.93600M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.25100M 0.04M -1.16800M 2.56M 0.17M
Deferred long term asset charges - - - - -
Non current assets total 1.90M 2.17M 2.39M 5.13M 2.92M
Capital lease obligations 0.07M 0.12M 0.07M 0.13M 0.07M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 6.12M -21.58000M -0.01500M 0.00000M 0.00000M
Change to liabilities - - - 0.61M 0.51M
Total cashflows from investing activities 6.11M -21.58000M -0.02100M - -
Net borrowings 5.00M -8.29500M 0.00000M -0.02000M 14.93M
Total cash from financing activities 51.53M 48.53M 15.28M 19.30M 36.61M
Change to operating activities - - - -0.72000M 0.72M
Net income -54.64800M -39.82700M -29.81500M -42.35000M -33.15200M
Change in cash 8.18M -2.82300M -9.22500M -18.25100M 7.17M
Begin period cash flow 12.77M 15.60M 24.77M 43.07M 35.90M
End period cash flow 20.95M 12.77M 15.55M 24.82M 43.07M
Total cash from operating activities -49.46500M -29.77000M -24.47900M -37.54900M -29.44000M
Issuance of capital stock 45.14M 56.08M 33.01M 19.21M 21.34M
Depreciation 0.23M 0.23M 0.23M 0.24M 0.25M
Other cashflows from investing activities 0.00300M - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - 0.11M -0.00600M - -
Sale purchase of stock 0.00000M 0.00000M -0.03000M 18.03M -
Other cashflows from financing activities - 0.75M 0.00700M 0.08M 15.27M
Change to netincome - - - 3.27M 2.23M
Capital expenditures 0.00300M 0.00000M 0.02M 0.00000M 0.02M
Change receivables - - - - -
Cash flows other operating - - - 0.69M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -18.25400M -
Change in working capital -4.26600M 2.41M -0.77800M 0.10M 1.23M
Stock based compensation 8.76M 5.33M 3.44M 3.27M 2.19M
Other non cash items 9.22M 2.09M 2.45M 1.20M 0.04M
Free cash flow -49.46800M -29.77000M -24.50000M -37.54900M -29.45700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACHV
Achieve Life Sciences Inc		 -0.09 1.76% 5.01 - 35.34 5.09 10.54 0.63 -2.4239
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Achieve Life Sciences Inc

22722 29th Dr. SE, Bothell, WA, United States, 98021

Key Executives

Name Title Year Born
Dr. Richard A. B. Stewart Exec. Chairman 1959
Mr. John A. Bencich M.B.A. CEO & Director 1977
Dr. Cindy Jacobs M.D., Ph.D. Pres, Chief Medical Officer & Director 1958
Mr. Jerry Wan Principal Accounting Officer 1982
Dr. Anthony Clarke Chief Scientific Officer 1956
Ms. Jaime Xinos Exec. VP of Commercial NA
Dr. Richard A. B. Stewart Executive Chairman 1959
Dr. Cindy Jacobs M.D., Ph.D. President, Chief Medical Officer & Director 1958
Ms. Jaime Xinos Executive Vice President of Commercial NA
Mr. Thomas B. King M.B.A. Executive Chairman 1955

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.